Dragonfly Therapeutics Initiates Phase 2 Study of HER2 Targeting TriNKET® DF1001 in Patients with Advanced Solid Tumors
– In Phase 1 DF1001 was well-tolerated and showed encouraging pharmacodynamic effects and clinical response, with tumor burden reductions across several...